Balance Medical(SH:688198) Bank of China Securities·2025-11-13 05:37Investment Rating - The investment rating for the company is "Buy" with a market price of RMB 108.83 and a sector rating of "Outperform" [1][5]. Core Insights - The company reported a revenue of RMB 382 million for the first three quarters of the year, representing a year-on-year growth of 30.58%. The net profit attributable to the parent company was RMB 93 million, up 57.93% year-on-year [5]. - The third quarter revenue was RMB 134 million, showing a year-on-year increase of 31.54%, while the net profit decreased by 9.39% year-on-year [5]. - The company is expected to continue launching new products, which will contribute to future growth, maintaining a positive outlook for the company's development [5][7]. Financial Performance Summary - For the years 2023 to 2027, the company is projected to achieve the following: - Revenue growth rates of 25.6% in 2023, 35.4% in 2024, and 37.5% in 2025 [9]. - Net profit growth rates of 21.1% in 2023, 27.0% in 2024, and 60.8% in 2025 [9]. - The estimated earnings per share (EPS) are expected to rise from RMB 0.84 in 2023 to RMB 3.27 in 2027 [9]. - The company maintains a high R&D expense ratio, with R&D expenses accounting for 30.81% of revenue in the first three quarters [10]. Product Development and Market Position - The company is in the process of launching multiple new products, with 8 products currently in the registration review phase [10]. - The collagen product line, particularly Collagen-I, is nearing approval and is expected to provide significant revenue growth [10].